Illumina closed its acquisition of liquid biopsy company Grail before a European Commission (EC) inquiry of the deal concluded. For that premature action, the commission on Wednesday imposed a â¬432 million fine -the maximum amount allowed under its rules. The commission contends both Illumina and Grail breached the standstill obligation of European Union merger law, which bars companies from combining until the regulator clears the deal.
[
add
]
[
|
|
...
]